Sign in

    David Szeto

    former Senior Associate in Biotech Equity Research at RBC Capital Markets

    David Szeto is a former Senior Associate in Biotech Equity Research at RBC Capital Markets, where he specialized in analyzing biopharmaceutical and life sciences companies. During his tenure from 2020 to 2021, he provided research coverage on firms like Corbus Pharmaceuticals and contributed expertise in earnings analysis and biotechnology sector trends. Szeto began his professional career after earning a PharmD from UC San Francisco, later holding roles in business development at Bayer and market access at 1798, before moving to Great Point Partners and Deep Track Capital following his RBC tenure. He holds advanced degrees in pharmacy and engineering, combining industry, analytical, and scientific credentials, though public performance rankings or FINRA registrations are not documented.

    David Szeto's questions to Corbus Pharmaceuticals Holdings (CRBP) leadership

    David Szeto's questions to Corbus Pharmaceuticals Holdings (CRBP) leadership • Q4 2020

    Question

    David Szeto of RBC Capital Markets inquired about Corbus's confidence in selecting candidates for its CB1 and CB2 programs and asked for clarification on the cash runway projection through Q1 2024, specifically how the quarterly operating expense run rate would decrease from $21 million to approximately $10 million.

    Answer

    Barbara White, Chief Medical Officer and Head of Research, expressed high confidence in selecting a CB1 inverse agonist candidate by year-end, citing promising data on metabolic activity and reduced brain occupancy. She noted the CB2 agonist program is slightly behind but also expects a candidate by year-end. CFO Sean Moran explained the reduced cash burn is due to the completion of expensive pivotal studies in CF and SSC and a recent reduction in workforce, confirming the new ~$10 million quarterly burn rate funds development into Phase 1.

    Ask Fintool Equity Research AI